Every material Form 8-K X4 Pharmaceuticals, Inc has filed with the SEC since September 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
X4 Pharmaceuticals filed an investor day presentation as Exhibit 99.1 to an 8-K and said it will post the deck on its website for its Investor Day event. The presentation updates the timeline for mavorixafor in primary chronic neutropenia, including full enrollment of the 4WARD Phase 3 study by the end of Q4 2026 and topline data in Q1 2028, with potential US FDA approval in late 2028 or early 2029.
The 8-K text refers to an October 29, 2029 Investor Day, while the exhibit is dated October 29, 2026.
4WARD Phase 3 trial expects full enrollment of 126 patients by end of Q4 2026 and topline data in Q1 2028.
Potential US FDA approval for primary chronic neutropenia is expected in late 2028 or early 2029.
Phase 2b 4STEPS G-CSF dose reduction study is planned to start in Q1 2027, with topline data in H1 2028.
On October 7, 2026, X4 Pharmaceuticals and its subsidiary X4 Therapeutics entered a Loan and Security Agreement with K2 HealthVentures providing term loans of up to $150.0 million. An $80.0 million first tranche funded at closing and was used to repay in full the Hercules loan, with a total payoff of approximately $78.7 million. For shareholders, the deal refinances existing debt and adds up to $70.0 million of possible further borrowing, but it carries variable-rate interest, secured liens, financial covenants, and a conversion feature that could issue common stock.
First tranche of $80.0 million funded October 7, 2026; up to $70.0 million more available at the company's request, subject to lender review and discretionary approval.
Hercules payoff of approximately $78.7 million, including $75.0 million of principal, ended the prior Hercules Loan Agreement and released its liens.
Cash interest is the greater of 8.55% or the WSJ prime rate plus 1.55%, plus 1.0% paid-in-kind interest; interest-only through October 1, 2029; maturity October 1, 2030.
Lenders may convert up to $15.0 million of principal into common stock at $3.2341 per share; minimum cash covenant applies from October 1, 2027 when market capitalization is below $800.0 million.
X4 Pharmaceuticals posted an updated corporate presentation on its website on September 8, 2026, filed as Exhibit 99.1 to a Form 8-K. The filing reiterates the timeline for its pivotal Phase 3 4WARD study of mavorixafor in chronic neutropenia, with full enrollment expected in Q4 2026 and top-line data expected in H1 2028, and it reports cash of $208 million as of June 30, 2026.
Presentation dated September 8, 2026, posted to the Investors section of the company website
Full enrollment in the 4WARD Phase 3 study expected in Q4 2026; top-line data expected in H1 2028
Cash of $208 million and 145.6 million fully diluted shares outstanding as of June 30, 2026; cash runway expected into 2029
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every X4 Pharmaceuticals, Inc filing is on SEC EDGAR ↗. 8-K briefs of other companies →